E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ST elevation myocardial infarction (STEMI) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if ticagrelor at treatment steady state (30 days maintenance therapy) will be associated to an improved microvascular function as compared to prasugrel in revascularized STEMI patients. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Provision of informed consent 2. Patients presenting with STEMI <12 hours 3. Successful PCI of the infarct-related vessel with a modern DES 4. Intermediate stenosis in non-infarct-related vessel (50-90%)
|
|
E.4 | Principal exclusion criteria |
1. history of myocardial infarction 2. Participation in another clinical study with an investigational product during the preceding 30 days 3. history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA) 4. History of intracranial haemorrhage 5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol) 6. severe liver dysfunction (Child-Pughscore 10–15) 7. congestive heart failure 8. cardiogenic shock 9. left ventricular ejection fraction < 35% 10. bleeding diathesis 11. age ≥ 75 or < 18 12. body weight < 60 kg 13. gout 14. coagulation disorders 15. severe pulmonary disease 16. pregnancy and breast feeding 17. limited life expectancy 18. platelet count < 100 000/mm3 19. history of drug addiction or alcohol abuse in the past 2 years 20. need for chronic nonsteroidal anti-inflammatory drug 21. creatinine clearance <30 mL/min or dialysis 22. chronic total occlusion (CTO) 23. Left main disease 24. allergy or contra-indication for ticagrelor or prasugrel 25. Contra-indication for adenosine 26. Patients unable to be followed on-site 27. Unable to undergo or contra-indications for MRI 28. Contra-indication for DES 29. Inability to obtain informed consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Index of microcirculatory resistance (IMR) at treatment steady state (1 month after primary PCI) in the infarct-related vessel, assessed with a pressure wire (Certus, St Jude Medical, St Paul,MN, USA).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1 month after primary PCI |
|
E.5.2 | Secondary end point(s) |
- The reactive hyperemia index (RHI) at treatment steady state (1 month after primary PCI), assessed with endopath system (Endopath; Itamar Medical Ltd., Cesarea, Israel). - The delta IMR between baseline and follow-up in both the infarct-related vessel and non-infarct related vessel. - The delta RHI between baseline and follow-up - The level of endothelial function as measured by several parameters (endothelin-1, NO synthase, e-NOS and dimethylarginine ) at follow-up |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- RHI: Baseline (1 day after primary PCI) and follow-up (1 month, 1 year and 1.5 year) - IMR: Baseline (directly after primary PCI) and follow-up ( 1 month) - Endothelial function blood samples: Baseline (directly after primary PCI) and follow-up (3 days, 1 month, 1 year and 1.5 year) - Palmar Collateral Flow Index (PCFI) at 1.5-year follow-up |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 2 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |